UroGen Pharma (URGN, Financial) continues to maintain strong support from analysts, as reflected in the latest rating from HC Wainwright & Co. On July 8, 2025, analyst Raghuram Selvaraju reiterated a 'Buy' rating for UroGen Pharma (URGN), a reaffirmation of the analyst’s previous stance.
The price target for UroGen Pharma (URGN, Financial) remains unchanged at $50.00 USD, signaling confidence in the company's potential amidst current market conditions. This target aligns with the prior assessment, showing consistent expectations from HC Wainwright & Co. with no percentage change in the projected stock price.
Investors are encouraged to note the continued positive outlook from HC Wainwright & Co. regarding UroGen Pharma's (URGN, Financial) performance potential. The maintained 'Buy' rating underscores the firm's confidence in the company's future growth trajectory.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for UroGen Pharma Ltd (URGN, Financial) is $34.38 with a high estimate of $50.00 and a low estimate of $16.00. The average target implies an upside of 154.82% from the current price of $13.49. More detailed estimate data can be found on the UroGen Pharma Ltd (URGN) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, UroGen Pharma Ltd's (URGN, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for UroGen Pharma Ltd (URGN, Financial) in one year is $19.16, suggesting a upside of 42.03% from the current price of $13.49. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the UroGen Pharma Ltd (URGN) Summary page.